Inhibition of ATM or ATR in Combination with Hypo-fractionated Radiotherapy Leads to a Different Immunophenotype on Transcript and Protein Level in HNSCC

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Oct 16

PMID 39411143

Authors

Julia Meidenbauer

Matthias Wachter

Sebastian R Schulz

Nada Mostafa

Lilli Zulch

Benjamin Frey

Rainer Fietkau

Udo S Gaipl

Tina Jost

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of head and neck tumors remains a challenge due to their reduced radiosensitivity. Small molecule kinase inhibitors (smKI) that inhibit the DNA damage response, may increase the radiosensitivity of tumor cells. However, little is known about how the immunophenotype of the tumor cells is modulated thereby. Therefore, we investigated whether the combination of ATM or ATR inhibitors with hypo-fractionated radiotherapy (RT) has a different impact on the expression of immune checkpoint markers (extrinsic), the release of cytokines or the transcriptome (intrinsic) of head and neck squamous cell carcinoma (HNSCC) cells.

Methods: The toxic and immunogenic effects of the smKI AZD0156 (ATMi) and VE-822 (ATRi) in combination with a hypo-fractionated scheme of 2x5Gy RT on HPV-negative (HSC4, Cal-33) and HPV-positive (UM-SCC-47, UD-SCC-2) HNSCC cell lines were analyzed as follows: cell death (necrosis, apoptosis; detected by AnxV/PI), expression of immunostimulatory (ICOS-L, OX40-L, TNFSFR9, CD70) and immunosuppressive (PD-L1, PD-L2, HVEM) checkpoint marker using flow cytometry; the release of cytokines using multiplex ELISA and the gene expression of Cal-33 on mRNA level 48 h post-RT.

Results: Cell death was mainly induced by the combination of RT with both inhibitors, but stronger with ATRi. Further, the immune phenotype of cancer cells, not dying from combination therapy itself, is altered predominantly by RT+ATRi in an immune-stimulatory manner by the up-regulation of ICOS-L. However, the analysis of secreted cytokines after treatment of HNSCC cell lines revealed an ambivalent influence of both inhibitors, as we observed the intensified secretion of IL-6 and IL-8 after RT+ATRi. These findings were confirmed by RNAseq analysis and further the stronger immune-suppressive character of RT+ATMi was enlightened. We detected the down-regulation of a central protein of cytoplasmatic sensing pathways of nucleic acids, RIG-1, and found one immune-suppressive target, EDIL3, strongly up-regulated by RT+ATMi.

Conclusion: Independent of a restrictive toxicity, the combination of RT + either ATMi or ATRi leads to comprehensive and immune-modulating alterations in HNSCC. This includes pro-inflammatory signaling induced by RT + ATRi but also anti-inflammatory signals. These findings were confirmed by RNAseq analysis, which further highlighted the immune-suppressive nature of RT + ATMi.

References

Burugu S, Dancsok A, Nielsen T . Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2017; 52(Pt 2):39-52. DOI: 10.1016/j.semcancer.2017.10.001. View

Formentini A, Braun P, Fricke H, Link K, Henne-Bruns D, Kornmann M . Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer. Int J Colorectal Dis. 2012; 27(10):1369-76. DOI: 10.1007/s00384-012-1456-0. View

Kartikasari A, Huertas C, Mitchell A, Plebanski M . Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. Front Oncol. 2021; 11:692142. PMC: 8294036. DOI: 10.3389/fonc.2021.692142. View

Voronov E, Shouval D, Krelin Y, Cagnano E, Benharroch D, Iwakura Y . IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003; 100(5):2645-50. PMC: 151394. DOI: 10.1073/pnas.0437939100. View

Cao X, Leonard K, Collins L, Cai S, Mayer J, Payton J . Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 2009; 69(22):8700-9. PMC: 2783758. DOI: 10.1158/0008-5472.CAN-09-1145. View

Almangush A, De Keukeleire S, Rottey S, Ferdinande L, Vermassen T, Leivo I . Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?. Cancers (Basel). 2022; 14(6). PMC: 8946626. DOI: 10.3390/cancers14061558. View

Pike K, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N . The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2.... J Med Chem. 2018; 61(9):3823-3841. DOI: 10.1021/acs.jmedchem.7b01896. View

Medina C, Mehrotra P, Arandjelovic S, Perry J, Guo Y, Morioka S . Metabolites released from apoptotic cells act as tissue messengers. Nature. 2020; 580(7801):130-135. PMC: 7217709. DOI: 10.1038/s41586-020-2121-3. View

Zhang C, Zhu M, Wang W, Chen D, Chen S, Zheng H . TNF-α promotes tumor lymph angiogenesis in head and neck squamous cell carcinoma through regulation of ERK3. Transl Cancer Res. 2022; 8(6):2439-2448. PMC: 8798551. DOI: 10.21037/tcr.2019.09.60. View

10.

Meliante P, Barbato C, Zoccali F, Ralli M, Greco A, de Vincentiis M . Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. Int J Mol Sci. 2022; 23(23). PMC: 9738355. DOI: 10.3390/ijms232315384. View

11.

Guo Y, Xie Y, Gao M, Zhao Y, Franco F, Wenes M . Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021; 22(6):746-756. PMC: 7610876. DOI: 10.1038/s41590-021-00940-2. View

12.

Chan L, Wang L, Chiang F, Lee K, Kuo P, Liang C . IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway. Oncotarget. 2016; 7(38):61820-61831. PMC: 5308693. DOI: 10.18632/oncotarget.11445. View

13.

Pal A, Kundu R . Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020; 10:3116. PMC: 6985034. DOI: 10.3389/fmicb.2019.03116. View

14.

Khushalani N, Ott P, Ferris R, Cascone T, Schadendorf D, Le D . Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. J Immunother Cancer. 2024; 12(3). PMC: 10921538. DOI: 10.1136/jitc-2023-007364. View

15.

Yang F, Yuan C, Chen F, Qin Z, Schmitt N, Lesinski G . Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer. J Exp Clin Cancer Res. 2024; 43(1):76. PMC: 10929116. DOI: 10.1186/s13046-024-03002-1. View

16.

Fiorentino D, Bond M, Mosmann T . Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989; 170(6):2081-95. PMC: 2189521. DOI: 10.1084/jem.170.6.2081. View

17.

David J, Dominguez C, Hamilton D, Palena C . The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel). 2016; 4(3). PMC: 5041016. DOI: 10.3390/vaccines4030022. View

18.

Want M, Bashir Z, Najar R . T Cell Based Immunotherapy for Cancer: Approaches and Strategies. Vaccines (Basel). 2023; 11(4). PMC: 10142387. DOI: 10.3390/vaccines11040835. View

19.

Oft M . IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014; 2(3):194-9. DOI: 10.1158/2326-6066.CIR-13-0214. View

20.

Tabasum S, Thapa D, Giobbie-Hurder A, Weirather J, Campisi M, Schol P . EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade. Cancer Immunol Res. 2023; 11(11):1493-1507. PMC: 10618652. DOI: 10.1158/2326-6066.CIR-23-0171. View